Discovery of Sennoside A as a Natural OGA Inhibitor That Ameliorates Parkinson's Disease by Restoring EphrinB2 O-GlcNAcylation
Research · 10.08.2026
DOI: 10.34133/research.1416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research, online erschienen am 10.08.2026. Verfasst von Guilin Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM …. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Down-regulated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) has been implicated in Parkinson’s disease (PD), and restoring O-GlcNAcylation levels in the central nervous system via O-GlcNAcase (OGA) suppression represents a potential therapeutic strategy for PD intervention. Nevertheless, naturally derived OGA inhibitors remain insufficiently explored, and the molecular mechanisms underlying OGA-inhibition-mediated restoration of O-GlcNAcylation to alleviate PD remain poorly defined. Here, a fluorescence-based high-throughput inhibitor screening platform was established and subsequently used to identify sennoside A (SA) as a potent OGA inhibitor from an in-house phytochemical library. As a competitive OGA inhibitor, SA exhibited potent anti-OGA activity both in vitro and in vivo, along with favorable blood–brain barrier permeability and a well-tolerated safety profile. Moreover, SA markedly elevated protein O-GlcNAcylation levels, which in turn attenuated neuroinflammatory response and ameliorated key PD-associated pathological and behavioral deficits. Mechanistically, SA directly inhibits OGA activity in neurons and microglia, predominantly enhancing the O-GlcNAcylation of EphrinB2 at the Ser40/Thr183 sites and stabilizing EphrinB2. This site-specific modification activates the EphrinB2–EphB4 signaling cascade and subsequently blunts mitogen-activated protein kinase-mediated neuroinflammation. Disruption of EphrinB2 O-GlcNAcylation by Ser40A/Thr183A mutation eliminates its neuroprotective function and abolishes the anti-PD effects of SA. Collectively, this work establishes the pharmacological inhibition of OGA as a promising therapeutic strategy for PD and identifies SA as a naturally occurring anti-PD agent that alleviates PD-associated pathological phenotypes by inhibiting OGA-mediated de-O-GlcNAcylation of EphrinB2.
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine…
- School of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin 124221, China.
- Jiangxi Provincial Key Laboratory of Natural Microbial Medicine Research, School of Pharmacy, Yichun University, Yichun 336000, China.
ORCID-Profile: Qiang Jin
Zitieren
APA
Wei, G., Jin, Z., Mi, H., Li, N., Wang, W., Song, Y., Jin, Q., Ge, G., & Liu, Y. (2026). Discovery of Sennoside A as a Natural OGA Inhibitor That Ameliorates Parkinson's Disease by Restoring EphrinB2 O-GlcNAcylation. Research. https://doi.org/10.34133/research.1416
Vancouver
Wei G, Jin Z, Mi H, Li N, Wang W, Song Y, et al. Discovery of Sennoside A as a Natural OGA Inhibitor That Ameliorates Parkinson's Disease by Restoring EphrinB2 O-GlcNAcylation. Research. 2026. doi:10.34133/research.1416
BibTeX
@article{Wei2026,
author = {Wei, Guilin and Jin, Zhuoan and Mi, Hanying and Li, Nan and Wang, Weiyu and Song, Yunqing and Jin, Qiang and Ge, Guangbo and Liu, Yong},
title = {Discovery of Sennoside A as a Natural OGA Inhibitor That Ameliorates Parkinson's Disease by Restoring EphrinB2 O-GlcNAcylation},
journal = {Research},
year = {2026},
doi = {10.34133/research.1416}
}
EUVIMED